Erschienen in:
26.08.2016 | Editorial
Real-World Experiences with Tenofovir Disoproxil Fumarate: Is this the “B-Ticket”?
verfasst von:
Norah A. Terrault
Erschienen in:
Digestive Diseases and Sciences
|
Ausgabe 10/2016
Einloggen, um Zugang zu erhalten
Excerpt
The preferred options for treatment of chronic hepatitis B viral (HBV) infection in countries without resource constraints are peginterferon, entecavir, or tenofovir disoproxil fumarate (TDF) [
1,
2]. For most clinicians, peginterferon is infrequently considered due to the greater complexity of monitoring, higher frequency of adverse effects and patient preference, which narrows the treatment options to TDF or entecavir. In the registration trials of treatment-naïve patients with chronic hepatitis B, both TDF and entecavir demonstrated high rates of on-treatment HBV DNA suppression and low rates of viral resistance coupled with excellent safety [
3,
4]. Given that TDF and entecavir have been approved therapies for HBV for more than a decade, data derived from “real-world” cohort studies have helped fill knowledge gaps regarding the use of these drugs in clinical practice. In the case of TDF, the issues of particular interest include: (1) the efficacy of TDF across a wider spectrum of patients including those less adherent than patients in clinical trials, and (2) the risks associated with longer-term use of TDF, especially the frequency of viral resistance and the risk of renal and bone toxicity. …